Show Me The Data: Why Payers Need to See RWE Used in New Indication Approvals
Is Real-World Evidence to be trusted? Well-documented data can make a difference to both FDA and formulary decision makers, as described by Precision for Value’s Jeremy Schafer, Senior Vice President, Access Experience and Dan Danielson, Senior Director, Access Experience, writing in Managed Healthcare Executive.
To read the full article please click here.